Zhi Cheng (Zhi Chen)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Multiple Myeloma

Chronic Kidney Disease

Prognostic Factors

Top Venues

Cancer gene therapy

American journal of hematology

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Dongjian Chen, Yu Zhu, Zhi Cheng, Songfu Jiang, Haiyan He, Wan-Ting Qiang, Fang Xiang, Xuedong Sun, Juan Du
A five-year follow-up clinical study of the B cell maturation antigen chimeric antigen receptor-T cell therapy HDS269B in patients with relapsed or refractory multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Dongjian Chen, Yu Zhu, Zhi Cheng, Songfu Jiang, Haiyan He, Wan-Ting Qiang, Fang Xiang, Xuedong Sun, Juan Du
A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (17) (2024)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Dongjian Chen, Xiaoxiang Wang, Zhi Cheng, Songfu Jiang, Hua Jiang, Weijun Fu, Fang Xiang, Xuedong Sun, Juan Du
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma. American journal of hematology 97 (12) (2022)
Juan Du, Runhong Wei, Songfu Jiang, Hua Jiang, Lu Li, Wanting Qiang, Haiyan He, Lin Shi, Qiuling Ma, Kang Yu, Xiaoyuan Zhang, Hanyi Ding, Xuedong Sun, Fang Xiang, Lin Zhu, Zhi Cheng, Weijun Fu
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status. American journal of hematology 97 (7) (2022)
Guoxing Zhao, Runhong Wei, Lei Feng, Yi Wu, Feng He, Mingxing Xiao, Zhi Cheng
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature. Cancer immunology, immunotherapy : CII (2021)